Top Industry Leaders in the Viscosupplementation Market
Latest Viscosupplementation Companies Update
OrthogenRx, Inc., a developer of viscosupplementation therapy for the relief of knee osteoarthritis (OA) pain, was acquired by Avanos Medical, Inc. for a reported $160 million. In addition to the $130 million paid at closing, the buyer will also be responsible for another $30 million in cash consideration that will be distributed upon the successful completion of certain growth milestones relating to the sales of the seller's commercial hyaluronic acid (HA) treatment products, GenVisc® 850 and TriVisc®. There is a potential market of $1 billion in the United States for the use of HA therapy to treat OA knee pain. GenVisc 850 and TriVisc are two new additions to Avanos' pain portfolio that have received FDA approval for the management of osteoarthritis knee pain in patients who have not found relief from more conventional treatments. Knee OA COOLIEF* therapy with cooled radiofrequency.
In a press release issued today, Nuvo Pharmaceuticals Inc. (TSX: MRV) (OTCQX: MRVFF) doing business as Miravo Healthcare (Miravo or the Company) announced the commercial introduction of NeoVisc+ 2 mL and NeoVisc ONE 4 mL in Canada. In September 2020, Health Canada gave the green light to the use of NeoVisc+ and NeoVisc ONE to alleviate pain and restore knee function in patients with degenerative (age-related) or mechanical (overuse) arthropathy. With the release of NeoVisc+ and NeoVisc ONE, medical professionals and patients now have access to cutting-edge choices for relieving knee pain.List of Viscosupplementation Key companies in the market
- Allergan
- Sanofi
- Hoffmann-La Roche
- Smith & Nephew Plc
- Zimmer Biomet
- Anika Therapeutics Inc.
- Ferring B.V.
- Bioventus
- FidiaFarmaceutici S.P.A.